Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Goodwill & Intangibles (2017 - 2025)

Puma Biotechnology's Goodwill & Intangibles history spans 9 years, with the latest figure at $41.4 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 19.05% year-over-year to $41.4 million; the TTM value through Dec 2025 reached $41.4 million, down 19.05%, while the annual FY2025 figure was $41.4 million, 19.05% down from the prior year.
  • Goodwill & Intangibles reached $41.4 million in Q4 2025 per PBYI's latest filing, down from $43.8 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $72.1 million in Q1 2021 to a low of $41.4 million in Q4 2025.
  • Average Goodwill & Intangibles over 5 years is $59.5 million, with a median of $61.5 million recorded in 2022.
  • Peak YoY movement for Goodwill & Intangibles: soared 82.74% in 2021, then decreased 19.05% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $66.1 million in 2021, then rose by 6.78% to $70.6 million in 2022, then fell by 13.79% to $60.9 million in 2023, then decreased by 16.0% to $51.1 million in 2024, then fell by 19.05% to $41.4 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Goodwill & Intangibles are $41.4 million (Q4 2025), $43.8 million (Q3 2025), and $46.3 million (Q2 2025).